Physician profile
Hadia Ashraf
NPI 1699702142
$12,403.25
in general payments reported to CMS, 2019-2025
50 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,605 · 2020: $1,633 · 2021: $2,458 · 2022: $1,596 · 2023: $1,595 · 2024: $1,396 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,110.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,503.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,250.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $666.19 | 2019-2025 | Jardiance, Synjardy, Combivent Respimat |
| Glaxosmithkline, LLC. | $636.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $605.36 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $594.56 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $568.49 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $568.07 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $561.82 | 2019-2023 | Xarelto |
| Lundbeck LLC | $497.78 | 2021-2025 | Rexulti |
| Abbott Laboratories | $464.07 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $383.28 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.81 | 2019-2025 | Xifaxan |
| Corcept Therapeutics | $357.05 | 2020-2025 | Korlym |
| Allergan, INC. | $327.17 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hadia Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.